Carcinoma News and Research RSS Feed - Carcinoma News and Research

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.
RCC benefit independent of sorafenib, sunitinib sequence order

RCC benefit independent of sorafenib, sunitinib sequence order

Sequential treatment with sorafenib followed by sunitinib is not superior to sunitinib followed by sorafenib in patients with advanced or metastatic renal cell carcinoma, suggests research published in European Urology. [More]
First-line axitinib ‘feasible’ in advanced, metastatic RCC

First-line axitinib ‘feasible’ in advanced, metastatic RCC

A Japanese single-institution study suggests that axitinib may be a feasible first-line option for patients with locally advanced or metastatic renal cell carcinoma. [More]
CLDF collaborates with Walgreens to offer free rapid HCV testing

CLDF collaborates with Walgreens to offer free rapid HCV testing

The Chronic Liver Disease Foundation announced today that it's collaborating with Walgreens to offer free hepatitis C (HCV) testing with the OraQuick HCV Rapid Test at more than 60 Walgreens retail pharmacies in 12 major cities throughout the country. [More]
Researchers uncover mechanism behind common mutation that helps cancer cells replicate limitlessly

Researchers uncover mechanism behind common mutation that helps cancer cells replicate limitlessly

More than 500,000 people in the United States die each year of cancer-related causes. Now, emerging research has identified the mechanism behind one of the most common mutations that help cancer cells replicate limitlessly. [More]
Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

An international team led by Weill Cornell Medical College investigators has illuminated the precise molecular steps that enable pancreatic cancer to spread to the liver -- the event that makes the most common form of the disease lethal. By understanding this process, investigators say their discovery can lead to targeted treatments that delay metastasis, and could offer clinicians a new biomarker to test for the earliest signs of pancreatic cancer. [More]
CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China today reported financial results for the three months ended March 31, 2015. [More]
MD Anderson researchers find significant clinical variations among liver cancer patients

MD Anderson researchers find significant clinical variations among liver cancer patients

Significant clinical variations exist among patients with the most common type of liver cancer called hepatocellular carcinoma (HCC), depending on the viral cause of the disease -hepatitis B virus (HBV) or hepatitis C virus (HCV). These differences suggest that hepatitis status should be considered when developing treatment plans for newly diagnosed patients, according to researchers at The University of Texas MD Anderson Cancer Center. [More]
Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

Simple blood test could help predict effectiveness of interferon-based therapy in HCV-infected patients

A simple blood test can be used to predict which chronic hepatitis C patients will respond to interferon-based therapy, according to a report in the May issue of Cellular and Molecular Gastroenterology and Hepatology, the basic science journal of the American Gastroenterological Association. [More]
Researchers identify three genes involved in choroid plexus carcinoma

Researchers identify three genes involved in choroid plexus carcinoma

Researchers have identified three genes that play a pivotal role in the brain tumor choroid plexus carcinoma (CPC), a discovery that lays the groundwork for more effective treatment of this rare, often fatal cancer. St. Jude Children's Research Hospital scientists led the study, which appears today in the journal Cancer Cell. [More]
Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets. [More]
Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite receives EMA clearance to begin CF102 Phase II trial for treatment of HCC patients in Europe

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today announced it recently received clearance from the European Medicines Agency to commence dosing patients in Europe in its global Phase II trial for CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. [More]
Chemotherapy benefit in nasopharyngeal carcinoma confirmed

Chemotherapy benefit in nasopharyngeal carcinoma confirmed

Addition of chemotherapy to radiotherapy significantly improves outcomes in patients with nonmetastatic nasopharyngeal carcinoma, shows a meta-analysis. [More]
Cardiff scientists develop novel anti-cancer stem cell compound

Cardiff scientists develop novel anti-cancer stem cell compound

Cardiff University scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumour forming cells common to breast, pancreas, colon and prostate cancers. [More]
Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH). [More]
Occurrence of advanced liver fibrosis similar for patients with HCV infection

Occurrence of advanced liver fibrosis similar for patients with HCV infection

Study results presented today at The International Liver Congress 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed. [More]
Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling. [More]
Study identifies BLU-554 as potential treatment option for HCC patients

Study identifies BLU-554 as potential treatment option for HCC patients

Findings were presented today at The International Liver CongressTM 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway. [More]
Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

Exome sequencing helps identify link between environmental exposures and mutational patterns in HCC

A new study presented today at The International Liver Congress 2015 shows that by using genomic analyses to understand how and when carcinogenic mutations occur in patients with hepatocellular carcinoma (HCC), it is possible to identify specific molecular profiles. It is hoped that these molecular profiles will help identify which patients would benefit from specific anticancer treatments. [More]

Long-term ETV or TDF therapy improves survival rate for Caucasian patients with CHB

Data revealed today at The International Liver Congress 2015 show that the long-term use of entecavir (ETV) or tenofovir (TDF) results in excellent 5-year survival for Caucasian patients with chronic hepatitis B (CHB), with more than 95% of patients surviving at 5 years and a significant proportion of deaths coming from liver-unrelated causes. [More]
Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

The botanical extract honokiol, a biologically active molecule isolated from the bark of Magnolia spp., holds promise as an adjunct treatment for aggressive bladder and kidney cancers, as reported in two new studies. New research on honokiol in bladder cancer was presented at the American Association for Cancer Research Annual Meeting 2015. [More]
Advertisement